Loading
A phase 1/2 trial of PTX-9908 Injection in hepatocellular carcinoma, run by TCM Biotech International Corp., now recruiting.
A Study of PTX-9908 Injection for Non-resectable HCC with TACE is a phase 1/2 interventional study registered as NCT03812874 by TCM Biotech International Corp., with 50 participants planned, started 2020-10-06 and due to reach its primary completion in 2026-08-30. Interventions recorded: PTX-9908 Injection and Placebo.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Transarterial chemoembolisation (TACE), Intermediate hepatocellular carcinoma (BCLC B), Hepatocellular carcinoma and the tag pipeline.
Shares Intermediate hepatocellular carcinoma (BCLC B), Hepatocellular carcinoma and the tag pipeline.
Shares Intermediate hepatocellular carcinoma (BCLC B), Hepatocellular carcinoma and the tag pipeline.
Shares Intermediate hepatocellular carcinoma (BCLC B), Hepatocellular carcinoma and the tag pipeline.
Shares Intermediate hepatocellular carcinoma (BCLC B), Hepatocellular carcinoma and the tag pipeline.
Shares Intermediate hepatocellular carcinoma (BCLC B), Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/